Is there a place for immunotherapy in MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Shahram Kordasti, Kings College London, London, UK. We asked, Is there a place for immunotherapy in MDS?

Kordasti overviews a network of immune dysregulation in MDS, including inflammation, immunosuppression, and cell death. He highlights heterogeneity in MDS and the need for better stratification of patients undergoing immunotherapy. He finishes by outlining methods to improve patient profiling for future trials, including when to consider immunotherapy.